<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655055</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00026241</org_study_id>
    <nct_id>NCT02655055</nct_id>
  </id_info>
  <brief_title>Bone Density in Voluntary Apheresis Blood Donors</brief_title>
  <acronym>ALTRUYST</acronym>
  <official_title>Randomized Longitudinal Study of Apheresis Voluntary Blood Donors' Bone Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versiti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Marquette University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Milwaukee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Versiti</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A longitudinal, randomized, controlled, single-center Phase IV clinical trial will be&#xD;
      performed to assess changes in bone mineral density (BMD) among voluntary apheresis blood&#xD;
      donors. The primary outcome measure will be clinically significant decline in BMD at the&#xD;
      lumbar spine assessed by dual-energy x-ray absorptiometry (DXA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apheresis blood donation maximizes an individual's donation by selecting specific blood&#xD;
      components that are used to save patient lives. Dramatic increases in the number of apheresis&#xD;
      procedures performed each year are apparent both domestically and internationally. Apheresis&#xD;
      requires the use of citrate anticoagulation, a substance that confers its anticoagulant&#xD;
      effect through chelation of cations, like calcium. A small number of cross-sectional studies&#xD;
      have reported that intermittent exposure to citrate through apheresis is associated with&#xD;
      significant declines in donor bone mineral density (BMD). In contrast, oral potassium citrate&#xD;
      of much lower dose has been used to treat low bone density with well-documented efficacy. The&#xD;
      impact of citrate exposure during apheresis, either positive or negative, is important given&#xD;
      that BMD is a significant risk factor for low trauma fracture, a problem that affects more&#xD;
      than 2M people in the U.S. annually. It is ultimately unknown what effect repeated apheresis&#xD;
      has on skeletal health. To address this knowledge gap, we will perform a Phase IV clinical&#xD;
      trial of apheresis blood donors using a cross-disciplinary, multi-institutional team. As&#xD;
      apheresis blood donation continues to affect more people, the importance of understanding the&#xD;
      effects of repeated exposure to citrate on donor skeletal health is essential in protecting&#xD;
      this precious community resource.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dual Energy XRay Absorptiometry - Total Lumbar Spine</measure>
    <time_frame>one year</time_frame>
    <description>The primary outcome measure is a decline in total lumbar spine bone mineral density that exceeds the technologist's least significant change (LSC) as assessed by DXA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dual Energy XRay Absorptiometry - Femoral Neck</measure>
    <time_frame>one year</time_frame>
    <description>A secondary outcome measure includes a decline in left or right femoral neck bone mineral density that exceeds the technologist's least significant change (LSC) as assessed by DXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual Energy XRay Absorptiometry - Total Hip</measure>
    <time_frame>one year</time_frame>
    <description>A secondary outcome measure includes a decline in total hip bone mineral density that exceeds the technologist's least significant change (LSC) as assessed by DXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual Energy XRay Absorptiometry - Total Body Composition</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Bone Density</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high frequency voluntary apheresis blood donation</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  eligible volunteer blood donor&#xD;
&#xD;
          -  ≥ 18, and, ≤ 65 years of age at enrollment&#xD;
&#xD;
          -  ≥ 1, and, ≤ 5 prior apheresis blood donation procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  female&#xD;
&#xD;
          -  age &lt; 18 or &gt; 65 years at enrollment&#xD;
&#xD;
          -  ineligible for whole blood donation&#xD;
&#xD;
          -  BMD Z-score &lt;(-2.0) or &gt;(2.0) at any measurement site upon baseline assessment&#xD;
&#xD;
          -  metal prosthesis at measurement site&#xD;
&#xD;
          -  weight &gt; 300 lbs (136 kg)&#xD;
&#xD;
          -  previous fracture of the lumbar spine or femoral neck&#xD;
&#xD;
          -  any fragility fracture, defined as a fracture resulting from a fall of standing height&#xD;
             or less, during adulthood (specifically ≥18 years of age at the time of fracture)&#xD;
&#xD;
          -  previous lumbar spinal fusion surgery&#xD;
&#xD;
          -  cystic fibrosis&#xD;
&#xD;
          -  emphysema&#xD;
&#xD;
          -  celiac disease&#xD;
&#xD;
          -  Crohn's disease&#xD;
&#xD;
          -  Current or past (&gt;1 month duration) use of medications known to affect BMD including,&#xD;
             not limited to: (phenytoin, phenobarbital, corticosteroids)&#xD;
&#xD;
          -  Current Osteoporosis Medication use including, but not limited to: (Forteo, oral&#xD;
             biphosphonates, Reclast, Prolia, calcitonin)&#xD;
&#xD;
          -  Unable or unwilling to donate high frequency apheresis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula E Papanek, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Marquette University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Bialkowski, MS</last_name>
    <role>Study Director</role>
    <affiliation>Versiti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert D Blank, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerome L Gottschall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versiti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng Zheng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Milwaukee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BloodCenter of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apheresis</keyword>
  <keyword>citrate anticoagulation</keyword>
  <keyword>blood donor</keyword>
  <keyword>bone</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 17, 2020</submitted>
    <returned>August 3, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

